These medications effectively manage T2DM but often cause adverse side effects such as insulin-related weight gain, glibenclamide-induced hypoglycemia, and metformin-linked gastrointestinal issues (Petrović et al., 2024). This evidence concerns the gene INS and type 2 diabetes mellitus.